重复给予改良聚肌苷酸-聚胞苷酸复合物后食蟹猴和恒河猴体内的干扰素诱导情况。
Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex.
作者信息
Sammons M L, Stephen E L, Levy H B, Baron S, Hilmas D E
出版信息
Antimicrob Agents Chemother. 1977 Jan;11(1):80-3. doi: 10.1128/AAC.11.1.80.
Abstract
Serum interferon activity was determined in 12 cynomolgus and 12 rhesus monkeys injected intravenously once daily for 10 days with from 0.1 to 6.0 mg of a stabilized polyriboinosinic acid . polyribocytidylic acid complex per kg, composed of polyriboinosinic acid . polyribocytidylic acid, poly-1-lysine, and carboxymethylcellulose [poly(ICLC)]. Interferon activity was detected 2 h after the first injection, with maximum activity occurring 8 h after the second injection. A period of hyporesponsiveness occurred after the third injection of poly(ICLC) in all monkeys and lasted until the sixth injection in the rhesus monkeys, when interferon activity again became more elevated. The delayed rebound was not as apparent in cynomolgus monkeys. Rhesus monkeys injected with 6 mg/kg did not exhibit serious side effects.
摘要
给12只食蟹猴和12只恒河猴静脉注射由聚肌苷酸·聚胞苷酸、聚-L-赖氨酸和羧甲基纤维素组成的稳定化聚肌苷酸-聚胞苷酸复合物[聚（ICLC）]，剂量为每千克0.1至6.0毫克，每日一次，持续10天，然后测定血清干扰素活性。首次注射后2小时检测到干扰素活性，第二次注射后8小时出现最大活性。所有猴子在第三次注射聚（ICLC）后都出现了一段低反应期，恒河猴持续到第六次注射，此时干扰素活性再次升高。延迟反弹在食蟹猴中不那么明显。注射6毫克/千克的恒河猴未出现严重副作用。
相似文献
1
Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex.
Antimicrob Agents Chemother. 1977 Jan;11(1):80-3. doi: 10.1128/AAC.11.1.80.
2
Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys.
J Infect Dis. 1979 Mar;139(3):267-72. doi: 10.1093/infdis/139.3.267.
3
Interferon induction in primates by stabilized polyriboinosinic acid-polyribocytidylic acid: effect of component size.
Infect Immun. 1981 Nov;34(2):416-21. doi: 10.1128/iai.34.2.416-421.1981.
4
A comparison of interferon responses to poly ICLC in males and females.
J Interferon Res. 1992 May;Spec No:85-90. doi: 10.1089/jir.1992.1992.85.
5
A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates.
J Infect Dis. 1975 Oct;132(4):434-9. doi: 10.1093/infdis/132.4.434.
6
Polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex [poly(ICL)] without carboxymethylcellulose (CMC): a new primate-effective interferon inducer.
Proc Soc Exp Biol Med. 1982 Feb;169(2):183-8. doi: 10.3181/00379727-169-41329.
7
A comparison of interferon responses to poly ICLC in males and females.
J Interferon Res. 1985 Summer;5(3):423-8. doi: 10.1089/jir.1985.5.423.
8
Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits.
Antimicrob Agents Chemother. 1980 Jan;17(1):49-54. doi: 10.1128/AAC.17.1.49.
9
Tumor response to interferon inducer and radiation effect of serum interferon levels.
J Biol Regul Homeost Agents. 1988 Jan-Mar;2(1):1-6.
10
Pharmacokinetics of interferon in blood, cerebrospinal fluid, and brain after administration of modified polyriboinosinic-polyribocytidylic acid and amphotericin B.
J Infect Dis. 1982 Dec;146(6):819-25. doi: 10.1093/infdis/146.6.819.
引用本文的文献
1
Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events.
Cancers (Basel). 2021 May 7;13(9):2237. doi: 10.3390/cancers13092237.
2
Nucleic Acid Immunotherapeutics for Cancer.
ACS Appl Bio Mater. 2020 May 18;3(5):2838-2849. doi: 10.1021/acsabm.0c00101. Epub 2020 Mar 16.
3
Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.
Cancer Immunol Immunother. 2018 Jul;67(7):1091-1103. doi: 10.1007/s00262-018-2164-6. Epub 2018 Apr 25.
4
The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.
Antiviral Res. 2015 May;117:75-98. doi: 10.1016/j.antiviral.2015.02.011. Epub 2015 Mar 5.
5
Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.
PLoS One. 2014 Feb 24;9(2):e89735. doi: 10.1371/journal.pone.0089735. eCollection 2014.
6
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.
PLoS Pathog. 2009 Apr;5(4):e1000373. doi: 10.1371/journal.ppat.1000373. Epub 2009 Apr 10.
7
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.
Invest New Drugs. 2001;19(1):89-92. doi: 10.1023/a:1006458232384.
8
Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits.
Antimicrob Agents Chemother. 1980 Jan;17(1):49-54. doi: 10.1128/AAC.17.1.49.
9
Variations in the contribution of induced interferon and adjuvanticity to the antiviral effect of different polyinosinic acid . polycytidylic acid formulations in mice infected with encephalomyocarditis virus.
Infect Immun. 1980 Sep;29(3):960-5. doi: 10.1128/iai.29.3.960-965.1980.
10
Modified polyriboinosinic-polyribocytidylic acid complex: modulation of toxicity for rabbits by alterations in components.
Antimicrob Agents Chemother. 1980 Sep;18(3):409-15. doi: 10.1128/AAC.18.3.409.
本文引用的文献
1
Tolerance to the induction of interferons by endotoxin and virus: role of a humoral factor.
Proc Soc Exp Biol Med. 1965 Aug-Sep;119(4):1227-32. doi: 10.3181/00379727-119-30421.
2
Kinetics of serum interferon response in mice after single and multiple injections of polyI-poly C.
Proc Soc Exp Biol Med. 1971 Feb;136(2):394-8. doi: 10.3181/00379727-136-35272.
3
The interferon refractory state: in vivo and in vitro studies of its mechanism.
J Immunol. 1971 Jan;106(1):134-42.
4
Polyriboinosinic-polyribocytidylic acid-induced interferons in calves.
Am J Vet Res. 1971 Jan;32(1):35-9.
5
Relationship between dose size and dose interval of polyinosinic polycytidylic acid and interferon hyporesponsiveness in mice.
Proc Soc Exp Biol Med. 1970 Nov;135(2):340-4. doi: 10.3181/00379727-135-35047.
6
Inhibition of biologic activity of poly I: poly C by human plasma.
Proc Soc Exp Biol Med. 1970 Feb;133(2):439-44. doi: 10.3181/00379727-133-34492.
7
Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes.
Proc Natl Acad Sci U S A. 1967 Sep;58(3):1004-10. doi: 10.1073/pnas.58.3.1004.
8
Studies on poly I:C toxicity in experimental animals.
Toxicol Appl Pharmacol. 1972 Dec;23(4):579-88. doi: 10.1016/0041-008x(72)90098-1.
9
Hyporeactivity of infection: potential limitation to therapeutic use of interferon-inducing agents.
Infect Immun. 1972 Nov;6(5):743-7. doi: 10.1128/iai.6.5.743-747.1972.
10
The effect of interferon, interferon inducers or interferon induced virus resistance on subsequent interferon production.
J Gen Virol. 1972 May;15(2):119-28. doi: 10.1099/0022-1317-15-2-119.
Zotero 插件